Istituto Nazionale per lo Studio e la Cura dei Tumori
6
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
67%
4 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer
Role: collaborator
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
Role: collaborator
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Role: lead
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Role: lead
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
Role: lead
Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion
Role: collaborator
All 6 trials loaded